[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3873 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 3873
To increase funding for cancer research by the National Cancer
Institute to be more in proportion to the mortality rates of cancer.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
June 10, 2025
Mr. Fitzpatrick (for himself and Mrs. Dingell) introduced the following
bill; which was referred to the Committee on Appropriations, and in
addition to the Committee on Energy and Commerce, for a period to be
subsequently determined by the Speaker, in each case for consideration
of such provisions as fall within the jurisdiction of the committee
concerned
_______________________________________________________________________
A BILL
To increase funding for cancer research by the National Cancer
Institute to be more in proportion to the mortality rates of cancer.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Knock Out Cancer Act'' or the ``KO
Cancer Act''.
SEC. 2. FINDINGS.
Congress finds the following:
(1) Cancer is one of the leading causes of death in the
world and has touched nearly every life, either directly or
indirectly.
(2) Cancer is the cause of nearly 1 out of every 4 deaths
in the United States, since 2000 totaling over 15 million
American lives.
(3) Efforts to increase awareness of cancer symptoms among
patients and clinicians would lead to earlier detection and
improvements in survival rates.
(4) Scientific understanding and research lead to
innovations in effective treatments, controls, and cures for
cancer.
(5) The National Cancer Institute has been a leader in
finding medical breakthroughs for treatment and therapies for
cancer patients.
(6) Through substantial investment in cancer research,
potentially even the tripling of necessary funding, the United
States will be best able to address the mortality rates of
cancer and the impacts on the patient population.
SEC. 3. INCREASING NCI BUDGET FOR CANCER RESEARCH.
To conduct or support cancer research, there is hereby
appropriated, for each of fiscal years 2026 through 2030, to the
National Cancer Institute, out of amounts in the Treasury not otherwise
appropriated, an amount that is equal to 25 percent of the total amount
appropriated to the National Cancer Institute for fiscal year 2022, to
remain available until expended. Amounts appropriated pursuant to the
preceding sentence shall be in addition to amounts otherwise made
available to the National Cancer Institute.
SEC. 4. REPORT TO CONGRESS ON CANCER DRUG SHORTAGES.
(a) Study.--The Secretary of Health and Human Services, acting
through the Commissioner of Food and Drugs, in collaboration with such
other agencies as the Secretary deems necessary, shall study the
reasons for cancer drug shortages, including--
(1) economic reasons;
(2) supply chain failures;
(3) delays and other complications relating to--
(A) the development of cancer drugs; and
(B) the approval of such drugs by the Food and Drug
Administration; and
(4) insufficient generic drugs and biosimilar biological
products.
(b) Report.--
(1) In general.--Not later than 1 year after the date of
enactment of this Act, the Secretary of Health and Human
Services, acting through the Commissioner of Food and Drugs,
shall complete the study under subsection (a) and submit a
report to the appropriate committees of the Congress on the
results of such study.
(2) Recommendations.--The report under paragraph (1) shall
include recommendations for addressing the reasons for cancer
drug shortages.
<all>